Restricted accessResearch articleFirst published online 1999-9
Differential Expression of Transforming Growth Factor-β1 and Transforming Growth Factor-β Receptors in Myometrium of Women With Failed Induction of Labor,No Labor,and Preterm Labor
Objective:Comparative analysis of transforming growth factor-β1 (TGF-β1) and TGF-β receptor type I and type II messenger RNA (mRNA) and protein expression in myometrium of women who had unsuccessful labor induction, with those without labor or in preterm labor complicated by chorioamnionitis.
Methods:Small segments of myometrium were collected from women who were undergoing cesarean delivery for unsuccessful labor induction (n = 5), elective cesarean without labor (n = 5), or cesarean delivery for complications related to preterm labor and chorioamnionitis (n = 5). Total RNA was isolated from these tissues and subjected to competitive quantitative reverse-transcription-polymerase chain reaction (Q-RT-PCR) to determine the level of TGF-β1, and TGF-β type I and type II receptor mRNA expression. Tissue sections were prepared from paraffin-embedded specimens and immunostained for TGF-β1 and receptor proteins using specific polycolonal antibodies. The data were analyzed by unpaired Student t test and Kruskal-Wallis analysis of variance.
Results:Myometrium from women who had unsuccessful labor induction expressed higher levels of TGF-β1 mRNA (2.21 ± 0.28 × 106 copies/μg of total cellular RNA) than those with preterm labor (4.53 ± 0.2 × 105 copies), or without labor [3.13 ± 2.6 × 104 copies (P < .05)]. The level of TGF-β type I receptor mRNA expression did not vary; however, type II receptor expression was significantly lower in myometrium from preterm labor (1.36 ± 0.36 × 105 copies) compared with those from unsuccessful labor induction (3.42 ± × 106 copies) or without labor (9.65 ± 3.2 × 105 copies). Immunoreactive TGF-β1 and TGF-β receptor proteins were present in all myometrial tissues, and their intensity reflected that of the mRNA expression in these tissues.
Conclusion:TGF-β1 and TFG-β type II receptors are expressed differently in myometrium of women who had unsuccessful labor induction compared with those without labor or with preterm labor complicated by chorioamnionitis. Because TGF-β is a key regulator of tissue remodeling which is central to initiation of normal labor, alterations in TGF-β and/or TGF-β receptor expression may lead to changes in the outcome of labor, at least at the myometrial level.
1. Osmers RG, Adelmann-Grill BC, Rath W, Stuhlsatz HW, Tschesche H, Kuhn W. Biochemical events in cervical ripening dilatation during pregnancy and parturition. J Obstet Gynecol1995;21:185-194.
2.
2. Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intra-amniotic infection. Infect Dis Clin North Am1997;11:135-176.
3.
3. Wray S. Uterine contraction and physiological mechanisms of modulation. Am J Physiol1993;264:C1-C18.
4.
4. Balducci J, Risek B, Gilula NB, Hand A, Egan JF, Vintzileos AM. Gap junction formation in human myometrium: A key to preterm labor?Am J Obstet Gynecol1993;168:1609-16915.
5.
5. Riemer RK, Heymann MA. Regulation of uterine smooth muscle function during gestation. Pediatr Res1998;44:615-627.
6.
6. Gibb W. The role of prostaglandins in human parturition. Ann Med1998;30:235-241.
7.
7. Wetzka B, Schafer W, Scheibel M, Nusing R, Zahradnik HP. Eicosanoids production by intrauterine tissues before and adter labor in short-term tissue culture. Prostaglandins1993;45:571-581.
8.
8. Dudley DJ, Collmer D, Mitchell MD, Trautman MS. Inflammatory cytokine mRNA in human gestational tissues: Implications for term and preterm labor. J Soc Gynecol Invest1996;3:328-335.
9.
9. Gomez R, Ghezzi F, Romero R, Munoz H, Tolosa-JE, Rojas I. Premature labor and intra-amniotic infection: Clinical aspects and role of the cytokines in diagnosis and pathophysiology. Clin Perinatol1995;22:281-342.
10.
10. Menon R, Swan KF, Lyden TW, Rote NS, Fortunato SJ. Expression of inflammatory cytokines (interleukin-1β and interleukin-6) in amniochorionic membranes. Am J Obstet Gynecol1995;172:493-500.
11.
11. Fortunato SJ, Menon RP, Swan KF, Menon R. Inflammatory cytokine (interleukins 1, 6 and 8 and tumor necrosis factor-alpha) released from cultured human fetal membranes in response to endotoxin lipopolysaccharide mirrors amniotic fluid concentrations. Am J Obstet Gynecol1996;174:1855-1862.
12.
12. Li Y, Ohls RK, Rosa C, Shah M, Richards DS, Christensen RD. Maternal and umbilical cord serum concentrations of granulocyte colony-stimulating factor in women with clinical chorioamnionitis. Obstet Gynecol1995;86:428-432.
13.
13. Hulboy DL, Rudolph LA, Matrisian LM. Matrix metalloproteineases as mediators of reproductive function. Mol Hum Reprod1997;3:27-45.
14.
14. Lei H, Furth EE, Kalluri R, et al. A program of cell death and extracellular matrix degradation is activated in the amnion before the onset of labor. J Clin Invest1996;98:1971-1978.
15.
15. Bryant-Greenwood GD, Yamamoto SY. Control of peripartal collagenolysis in the human chorion-decidua. Am J Obstet Gynecol1995;172:63-70.
16.
16. Takahashi S, Sato T, Ito A, et al. Involvement of protein kinase C in the interleukin 1 alpha-induced gene expression of matrix metalloproteinases and tissue inhibitor-1 of metalloproteinases (TIMP-1) in human uterine cervical fibroblasts. Biochem Biophys Acta1993;1220:57-65.
17.
17. Lockwood CJ, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med1999;27:5-20.
18.
18. Romero R, Wu YK, Oyarzun E, Hobbins JC, Mitchell MD. A potential role for epidermal growth factor/alpha transforming growth factor in human parturition. Eur J Obstet Gynecol Reprod Biol1989;33:55-60.
19.
19. Fortunato SJ, Menon R, Lambardi Sj. Interleukin-10 and transforming growth factor-β inhibit amnicohorion turmor necrosis factorsα by contrasting mechanisms of action: Therapeutic implications in prematurity. Am J Obstet Gynecol1997;177:803-809.
20.
20. Bry K, Lappalainen U. Interleukin 4 and transforming growth factor-beta 1 modulate the production of interleukin-1 receptor antagonist and of prostaglandin E2 by decidual cells. Am J Obstet Gynecol1994;170:1194-1198.
21.
21. Lawrence DA. Transforming growth factor-beta: A general review. Eur Cytokine Netw1996;7:363-374.
22.
22. Tang XM, Ghahary A, Chegini N. The interaction between transforming growth factor β and relaxin leads to modulation of matrix and matrix metalloproteinases expression in human uterus [abstract]. J Soc Gynecol Invest1996;3:256-256.
23.
23. Goldenberg RL, Mercer BM, Iams JD, et al. The preterm prediction study: Patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. Am J Obstet Gynecol1997;177:8-12.
24.
24. Ma C, Chegini N. Modulation of matrix metalloproteinases and tissue inhibitor of MMPs (TIMPs) expression in human myometrial smooth muscle cell by transforming growth factor β1. Mol Hum Reprod1999;5-5 (in press).
25.
25. Mitchell MD. The regulation of decidual prostaglandin biosynthesis by growth factors, phorbol esters, and calcium. Biol Reprod1991;44:871-874.
26.
26. Kniss DA, Zimmerman PD, Fertel RH, Iams JD. Pro-inflammatory cytokines interact synergistically with epidermal growth factor to stimulate PGE2 production in amnion-derived cells. Prostaglandins1992;44:237-244.
27.
27. Watanabe H. Epidermal growth factor in urine of pregnant women and in amniotic fluid throughout pregnancy. Gynecol Endocrinol1990;4:43-50.
28.
28. Tahara M, Tasaka K, Masumoto N, Adachi K, Adachi H, Ikebuchi Y, et al. Expression of messenger ribonucleic acid for epidermal growth factor (EGF), transforming growth factor-alpha (TGF-α, and EGF receptor in human amnion cells: Possible role of TGF-αin prostaglandin E2 synthesis and cell proliferation. J Clin Endocrinol Metab1995;80:138-146.
29.
29. Faber BM, Metz SA, Chegini N. Immunolocalization of eicosanoid enzymes and growth factors in human myometrium and fetoplacental tissues in failed labor inductions. Obstet Gynecol1996;88:174-179.
32. Chegini N, Zhao Y, Williams RS, Flanders KC. Human uterine tissue throughout the menstrual cycle expresses TGF-β1, TGF-β2, TGF-β3 and TGF-β type II receptor mRNA and protein and contain 125I-TGF-β1 binding sites. Endocrinology1994;135:439-449.
33.
33. Tang X-M, Dou Q, Zhao Y, Davis J, McLean WF, Chegini N. Expression of mRNA and protein for TGF-β isoforms and TGF-β type I-III receptor in human myometrial smooth muscle cells and their effect on DNA synthesis and protein degradation in vitro. Mol Hum Reprod1997;3:233-240.
34.
34. Dou Q, Zhao Y, Tarnuzzer RW, et al. Suppression of TGF-βs and TGF-β receptors mRNA and protein expression in leiomyomata in women receiving gonadotropin releasing hormone agonist therapy. J Clin Endocrinol Metab1996;81:3222-3230.
35.
35. Dou Q, Tarnuzzer RW, Williams RS, Schultz GS, Chegini N. Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: A mechanism for gonadotropin releasing hormone agonist induced tumour regression. Mol Hum Reprod1997;3:1005-1014.
